Brief: Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As Planned After Third Review
08/05/2024 12:25
May 8 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* ALTERITY THERAPEUTICS PHASE 2 DATA MONITORING COMMITTEE
RECOMMENDS CONTINUING CLINICAL TRIAL AS PLANNED AFTER THIRD
REVIEW
* ALTERITY THERAPEUTICS LTD - TOP-LINE DATA EXPECTED IN
JANUARY
2025
* ALTERITY THERAPEUTICS LTD - ATH434-201 TRIAL ON TRACK TO
COMPLETE IN NOVEMBER 2024
* ALTERITY THERAPEUTICS LTD - INDEPENDENT DMC FINDS NO
SAFETY
CONCERNS FOR ATH434-201
Source text for Eikon: ID:nGNX7XyXdf
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital